[Expert consensus on the use of pegylated recombinant human granulocyte colony-stimulating factor in the treatment of hematologic malignancies (2026 edition)].

Neutropenia is one of the most common hematologic toxicities during the treatment of hematologic malignancies. It can lead to delays in subsequent treatments, dose reduction of chemotherapeutic agents, or even treatment discontinuation. Furthermore, neutropenia increases the risk of febrile neutropenia and severe infections, which adversely affect patient prognosis. Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) is effective in preventing and treating neutropenia, and is widely used in the treatment of hematologic malignancies and hematopoietic stem cell transplantation (HSCT). To further promote the standardized application of PEG-rhG-CSF in hematological malignancies, the Hematology Oncology Committee of China Anti-Cancer Association organized domestic experts in the related fields, based on current evidence-based medical data and clinical practice, to focus on the clinical application of PEG-rhG-CSF in hematologic malignancies, hematopoietic stem cell mobilization and hematopoietic function reconstitution after HSCT. Eight recommendation opinions were finally proposed to guide the standardized use of drugs in clinical practice.